Kymera Therapeutics Inc (KYMR) Stock at a key inflection point
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Why Kymera Therapeutics Inc (NASDAQ:KYMR) Stock went up 97.44% in Last Year?
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Is Kymera Therapeutics Inc (KYMR) Stock A Better Investment Than Its Rivals?
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Does A Technical Metric Suggest That Kymera Therapeutics Inc (KYMR) Stock Is Ready To Rise?
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Are Options A Good Investment Right Now? Kymera Therapeutics Inc (KYMR) Stock
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Consensus Analyst Estimated Price Target of $52.00 for Kymera Therapeutics Inc (NASDAQ:KYMR) Stock
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Kymera Therapeutics Inc (KYMR) Stock Experiences Incredible Growth
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
It’s Better to Hope for Prosperity than Become Adversary: Kymera Therapeutics Inc (KYMR) Stock
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
Kymera Therapeutics Inc (KYMR) Stock at a key inflection point
Oppenheimer raised the price target for the Kymera Therapeutics Inc (NASDAQ:KYMR) stock to “an Outperform”. The rating was released on April 22, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on January 03, 2024, from Buy to Neutral and set the price objective to $30. In […]
